Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
Agree with everything you say
But funny how the pumper arrive now the MMS have had their fun!
Ride the wave
Ps have never sold so not taken advantage but have added. It will come good.
Don’t be their ***** and research!!
At this stage, I try to deal with facts:
Fact: AVCT have proven their patented affirmers is a decent alternative to antibody diagnostic testing - mass market, future testing will be HUGE.
If AVCT commercialise their LFT - superb revenues incoming.
If they don’t, a big pharma will come in and buy them for huge money.
Either way - £4 per share will be regarded as a measley offer against recent company sales.
That leaves the cancer side.
Happy days I say.
Be patient!!
I didn’t sell at 2.80 because I didn’t feel that was enough.
By jove I wish I had of done, but if I had, I’d have been putting the lions share of that back into AVCT at £1.10 - my original stake and all of the six figure profit.
We can only blame ourselves - none of us, none of us, have a crystal ball.
The price today is a reflection of the impatience of the market and the large percentage of retail investors, particularly sadly who hold/held AVCT. I also believe one (or maybe more than one) institutions have been “selling down”. Again, this is a reflection of delayed timescales and nothing more IMO.
The share price today represents an absolute gift IMO. AVCT has proven the affirmer and the LFT will sell in huge numbers. If people have time on their hands they should again be listening the business update only 2 months ago. The vox markets interview in February is another very good listen. The annual update RNS was also highly informative and shows exactly what AVCT is all about - rest assured they are working extremely hard and ‘at pace’ to deliver on all fronts, which will, I am sure, add significant value to the SP and yes will confidently take us back to real value - which IMO is far in excess of £2.80!
Sentiment is down but the science of what the company has now proven is worth far beyond anyone’s wildest expectations. Be patient and don’t be hasty - Rome was not built in days !!
I think most people had written Blautix off - clearly not and I agree that why would the company bother to update on the results if they were bad. I have added today. In Peyton's own words "big year for 4D Pharma" …. some huge readouts this year coming, starting in June. Two key brokers from the US have put the share price at $35 and $40 at 'fair value' - that's three times the current Share Price! Buy, buy, buy IMO. Big things are coming. Just be patient - HUGE buying opportunity.
Just been reading the last few RNSs. The below are all direct quotes:
“On the basis of these excellent initial data, the Company will now progress to a full clinical validation with a larger number of patient samples to CE mark the test for professional use, aiming to bring the test to market in Europe around the end of the first quarter of this year.
These data from the first clinical studies will allow us to quickly progress with confidence into the full clinical validation of the test, manufactured at scale, at our clinical trial sites in the UK and the EU. I am confident that these data will accelerate our commercial discussions regarding the roll-out of the test when it is approved for professional use.
The partnership with Mologic will provide a faster route to market for Avacta's rapid antigen test by CE marking it for professional use under Mologic's existing ISO13485 quality system. The CE mark will then be transferred to Avacta when it receives ISO13485 accreditation, which is expected by the end of March 2021.
Now that we have developed a robust lateral flow test architecture, we can easily insert Affimer reagents that that can be very rapidly developed for new variants if necessary, and indeed in response to any other future pandemic virus.
Our next key milestone is full clinical validation and CE marking of our lateral flow antigen test which we anticipate will be around the end of this quarter and I look forward to updating the market when that milestone is achieved."
RNS this week. They probably needed today to speak to Boris !!
Just been reading the last few RNSs. The below are all direct quotes:
“On the basis of these excellent initial data, the Company will now progress to a full clinical validation with a larger number of patient samples to CE mark the test for professional use, aiming to bring the test to market in Europe around the end of the first quarter of this year.
These data from the first clinical studies will allow us to quickly progress with confidence into the full clinical validation of the test, manufactured at scale, at our clinical trial sites in the UK and the EU. I am confident that these data will accelerate our commercial discussions regarding the roll-out of the test when it is approved for professional use.
The partnership with Mologic will provide a faster route to market for Avacta's rapid antigen test by CE marking it for professional use under Mologic's existing ISO13485 quality system. The CE mark will then be transferred to Avacta when it receives ISO13485 accreditation, which is expected by the end of March 2021.
Now that we have developed a robust lateral flow test architecture, we can easily insert Affimer reagents that that can be very rapidly developed for new variants if necessary, and indeed in response to any other future pandemic virus.
Our next key milestone is full clinical validation and CE marking of our lateral flow antigen test which we anticipate will be around the end of this quarter and I look forward to updating the market when that milestone is achieved."
I think we will get an RNS tomorrow. If we don’t, don’t get spooked !
RNS will definitely be this week.
HUGE week coming that’s for sure.
So in theory we could get 1 RNS saying:
CV complete
CE mark complete
Avct ISO accredited and
Gov orders (U.K. or elsewhere too!)
Then we’d really have rockets !
Night all !
In my view, we will have an RNS tomorrow.
The RNS on 17 March states:
“In addition, Duncan Peyton (Chief Executive Officer) and Alex Stevenson (Chief Scientific Officer) intend to subscribe for, in aggregate, $2.0 million (£1.44 million) once the Company has released the results for the year ended 31 December 2020, expected to be on or around 25 March 2021.” It is 25 March tomorrow and they have been on-point with dates thus far.
DP, CEO stated in the 17 March RNS:
“The additional funds that these combined activities deliver will enable 4D pharma to continue the rapid pace of development on our pipeline of Live Biotherapeutics, including lead oncology program, MRx0518 targeting a range of cancers, as well as other therapeutic areas such as neurological conditions. We have a robust line up of milestones set for 2021 and with both our new US institutional support and upcoming NASDAQ listing, we look forward to providing updates from our novel, single-strain LBP programs to our expanded global audience.”
Now tell me what’s not to like ?!
This is going one way. Superb prospects. Ignore the noise and take advantage of the ridiculously low share price !
In my view, the next few RNS’s will be monumental.
pr*t
Anyone saying this will be £1 by Friday knows nothing about shares. At £1.10 one of the big pharms in the world has taken a bucket load. The CEO and next in-line have both thrown over £1million of their own money at it. Everyone needs to calm down. Yep grossly annoying that we are at £1.18 and were £1.50 but anyone who is well researched on 4D and understands the market knows that this will recover as quickly as it has come down. My advice - buy or hold. Very simple. DDDD has some of the best prospects on AIM and will deliver.
We are red because as usual the first few minutes of trading almost never reflects the actual meaning of the RNS. This is absolutely HUGE news for 4D Pharma. This level of cash from IIs tells me all I need to know. 4D going exactly the same way as avacta IMO. To the moon.
Derampers keep trying to swamp it out with negative comments (clear and obvious) so I will say it again !
The RNS dated 8 February states:
"The Company looks forward to providing the market with a detailed business update later this month once definitive clinical data from the lateral flow test evaluation is available."
The detailed business update is yet to arrive, as is the definitive clinical data. It will therefore arrive between now and cob Friday.
In RNS dated 16 Feb it states:
"On the basis of these excellent initial data, the Company will now progress to a full clinical validation with a larger number of patient samples to CE mark the test for professional use, aiming to bring the test to market in Europe around the end of the first quarter of this year."
Consequently I am expecting this definitive clinical data and detailed business update to arrive in the next few trading days !